Perquin, M.J.

patient hbeag hbeag seroconversion seroconversion hepatitis therapy treatment fl ares hepatitis b nucleo recurrence study analogue month level lamivudine virologic withdrawal fl ares follow-up follow-up evaluation 6 months response virus frequency resistance serum infection hbsag on-therapy fl ares gastroenterology development durability virologic recurrence hbv dna monotherapy antigen hepatology withdrawal serologic disease hepatitis b virus subject lamivudine therapy decompensated liver disease analysis outcome discontinuation hbv-dna –liver pancreas lam monotherapy evaluation hbv-dna levels /or virologic recurrence on-therapy hbeag loss liver remission drug resistance center rotterdam hepatitis fl ares erasmus mc university type b hepatitis hepatitis b patients serologic recurrence relapse entecavir course consolidation therapy agent hbv infection disease remission range analogue-induced chu cm hbsag loss result exacerbation 28 –103 mo consolidation treatment discontinuation